Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520790 | 0.91 | RIPK1 (0.41) | MRGPRX4KMORIPK1 | |
| SCHEMBL12828558 | 0.90 | BRAF (0.38) | MRGPRX4BRAFRIPK1MAPTLMNA | |
| SCHEMBL8520796 | 0.83 | NR1H2 (0.39) | BRAFKMORIPK1 | |
| SCHEMBL8527906 | 0.81 | RIPK1 (0.42) | BRAFRIPK1TP53 | |
| SCHEMBL8520679 | 0.76 | EGLN2 (0.43) | EGLN1 | |
| SCHEMBL12935693 | 0.70 | KMO (0.41) | BRAFKMORIPK1 | |
| SCHEMBL12828249 | 0.69 | BRAF (0.42) | BRAFRIPK1 | |
| SCHEMBL6123299 | 0.69 | EGLN1 (0.46) | KMORIPK1EGLN1 | |
| Hydrochloric Acid SCHEMBL1484193 | 0.69 | EGLN1 (0.46) | KMORIPK1EGLN1 | |
| SCHEMBL8526969 | 0.68 | EGLN2 (0.39) | MRGPRX4MAPTTHRBFFAR4EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | MRGPRX4 2819/4885BRAF 1279/4885KMO 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.